Related Experiment Video

Updated: Aug 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

The role of calcium antagonists in stroke prevention

William J Elliott1, Armin Bandari

  • 1Department of Preventive Medicine, Rush Medical College, Rush University Medical Center, 1700 West Van Buren Street, Chicago, IL 60612, USA. welliott@rush.edu

Journal of Clinical Hypertension (Greenwich, Conn.)
|April 29, 2005
PubMed

Insights

Lowering high blood pressure reduces stroke risk. Calcium antagonists show a large stroke reduction but increase heart failure risk, according to a meta-analysis of antihypertensive medications.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Elevated blood pressure is a major risk factor for stroke.
  • The comparative effectiveness of different antihypertensive medication classes for stroke prevention, independent of blood pressure reduction, remains debated.

Purpose of the Study:

  • To evaluate whether specific antihypertensive drug classes offer stroke risk reduction beyond their blood pressure-lowering effects.
  • To assess the impact of calcium antagonists compared to other antihypertensive agents on stroke and heart failure risk.

Main Methods:

  • A meta-analysis of clinical trials published up to December 2004 was conducted.
  • Compared outcomes for calcium antagonists (dihydropyridine and nondihydropyridine subclasses) against diuretics and beta blockers.

Main Results:

  • Calcium antagonists demonstrated the largest point estimate for stroke reduction compared to placebo.
  • When combined, calcium antagonists showed a significant 9% stroke reduction versus diuretics or beta blockers.
  • However, initial calcium antagonist use significantly increased heart failure risk by 29%.

Conclusions:

  • While calcium antagonists may offer some stroke risk reduction, this benefit is accompanied by a significant increase in heart failure risk.
  • The findings suggest a complex risk-benefit profile for calcium antagonists in hypertension management.
  • Further research with newer trials is warranted to refine these estimates.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...